Azilsartan Impurity 140 NEW

Product Information

Product Number: A006140

English Name: Azilsartan Impurity 140

English Alias: 2-methoxy-1-((2'-(5-oxo-2,5-dihydro-1,2,4-oxadiazol-3-yl)-[1,1'-biphenyl]-4-yl)methyl)-1H-benzo[d]imidazole-7-carboxylic acid

CAS Number: 147403-35-8

Molecular Formula: C₂₄H₁₈N₄O₅

Molecular Weight: 442.42

Advantages

Well-defined structure and high stability, enabling precise analysis of by-product formation mechanisms during azilsartan synthesis, such as benzimidazole ring construction and oxadiazole introduction, to optimize processes and reduce impurity generation;

As a reference standard with nitrogen heterocyclic and carboxyl structures, it provides a standard substance for detecting impurities with complex functional groups in drugs, improving the quantitative accuracy of methods like HPLC and LC-MS;

Helps study the impact of heterocyclic structures on drug stability and toxicological properties, providing a scientific basis for impurity control strategies.

Applications

Drug Development: Used as an impurity reference standard to identify and quantify Impurity 140 in azilsartan preparations, evaluating the purity of APIs and formulations;

Quality Control: Acting as a standard substance to validate the sensitivity and specificity of detection methods (e.g., HPLC, LC-MS), ensuring the impurity content meets pharmacopoeia and regulatory requirements during production;

Stability Studies: Investigating the degradation behavior of this impurity under light, high temperature, and high humidity conditions to evaluate its impact on azilsartan formulation stability, assisting in determining storage conditions and shelf life.

Background Description

Research Status

Detection Method Optimization: Establishing trace detection methods for this impurity using techniques such as ultra-high-performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) and high-resolution mass spectrometry (HRMS), achieving precise analysis with sensitivity reaching the ppb level;

Synthesis Process Improvement: Optimizing the synthesis route by adjusting catalyst types, reaction temperature, and raw material ratios to reduce impurity generation and developing high-purity impurity synthesis processes;

Toxicological Evaluation: Studying the potential toxicity of this impurity through in vitro cytotoxicity experiments and animal models to provide data support for formulating reasonable impurity limit standards;

Crystal Form and Physicochemical Properties: Investigating the crystal form characteristics of this impurity and its impact on the physical stability of drug formulations to improve the azilsartan quality control system.